Haverkamp L, Parry K, van Berge Henegouwen M I, van Laarhoven H W, Bonenkamp J J, Bisseling T M, Siersema P D, Sosef M N, Stoot J H, Beets G L, de Steur W O, Hartgrink H H, Verspaget H W, van der Peet D L, Plukker J T, van Etten B, Wijnhoven B P L, van Lanschot J J, van Hillegersberg R, Ruurda J P
Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands.
Dis Esophagus. 2016 Jul;29(5):435-41. doi: 10.1111/dote.12347. Epub 2015 Mar 30.
Esophageal and gastric cancer is associated with a poor prognosis since many patients develop recurrent disease. Treatment requires specific expertise and a structured multidisciplinary approach. In the Netherlands, this type of expertise is mainly found at the University Medical Centers (UMCs) and a few specialized nonacademic centers. Aim of this study is to implement a national infrastructure for research to gain more insight in the etiology and prognosis of esophageal and gastric cancer and to evaluate and improve the response on (neoadjuvant) treatment. Clinical data are collected in a prospective database, which is linked to the patients' biomaterial. The collection and storage of biomaterial is performed according to standard operating procedures in all participating UMCs as established within the Parelsnoer Institute. The collected biomaterial consists of tumor biopsies, blood samples, samples of malignant and healthy tissue of the resected specimen and biopsies of recurrence. The collected material is stored in the local biobanks and is encoded to respect the privacy of the donors. After approval of the study was obtained from the Institutional Review Board, the first patient was included in October 2014. The target aim is to include 300 patients annually. In conclusion, the eight UMCs of the Netherlands collaborated to establish a nationwide database of clinical information and biomaterial of patients with esophageal and gastric cancer. Due to the national coverage, a high number of patients are expected to be included. This will provide opportunity for future studies to gain more insight in the etiology, treatment and prognosis of esophageal and gastric cancer.
食管癌和胃癌的预后较差，因为许多患者会出现疾病复发。治疗需要专业技能和结构化的多学科方法。在荷兰，这类专业技能主要存在于大学医学中心（UMC）和一些专门的非学术中心。本研究的目的是建立一个全国性的研究基础设施，以更深入地了解食管癌和胃癌的病因及预后，并评估和改善对（新辅助）治疗的反应。临床数据收集于一个前瞻性数据库，该数据库与患者的生物材料相关联。生物材料的收集和存储按照帕雷尔斯诺尔研究所规定的所有参与的大学医学中心的标准操作程序进行。收集的生物材料包括肿瘤活检组织、血液样本、切除标本的恶性和健康组织样本以及复发活检组织。收集的材料存储在当地的生物样本库中，并进行编码以尊重捐赠者的隐私。在获得机构审查委员会对该研究的批准后，第一名患者于2014年10月被纳入。目标是每年纳入300名患者。总之，荷兰的八所大学医学中心合作建立了一个全国性的食管癌和胃癌患者临床信息及生物材料数据库。由于覆盖全国，预计将纳入大量患者。这将为未来的研究提供机会，以更深入地了解食管癌和胃癌的病因、治疗及预后。
